Med-IQ

Course Listings: Hematology

All Results (4)
Format: Live Events (0) Online Activities (4)

Tumor Lysis Syndrome in a Rapidly Evolving Treatment Landscape

View Course

Format: E-Publication

    Maximum Credits:
  • 0.75 AMA PRA Category 1 Credit(s)

Course Description: This interactive, digital CME publication integrates current clinical evidence and an algorithmic approach to assessing the risk of and planning prophylaxis for tumor lysis syndrome (TLS) in patients for whom an anticancer therapeutic strategy is being developed. Expert insight on responses to patient-case scenarios from a national survey help highlight best…More


Improving Multiple Myeloma Care in a Rapidly Evolving Field

View Course

Format: Webcast

    Maximum Credits:
  • 1.0 AMA PRA Category 1 Credit(s)

Course Description: This CME Webcast explores clinical management strategies for multiple myeloma. Experts in the field use patient cases to discuss current clinical evidence and treatment guidelines for newly diagnosed and relapsed/refractory disease, with a focus on patient-, disease-, and treatment-related factors that guide therapeutic decisions.


Recognizing Gaucher’s Disease in the Hematology Clinic

View Course

Format: Presentation Points

    Maximum Credits:
  • 0.5 AMA PRA Category 1 Credit(s)

Course Description: This transcript-based, CME-certified Presentation Points publication summarizes a satellite symposium presented by Pramod K. Mistry, MD, PhD, FRCP, and Neal J. Weinreb, MD, FACP, nationally renowned experts in Gaucher’s disease (GD) type 1. Faculty present strategies for recognizing symptoms early in the disease course and discuss the implications of…More


Managing CLL With Oral Agents

View Course

Format: Webinar

    Maximum Credits:
  • 1.0 AMA PRA Category 1 Credit(s)
  • 1.0 California Board of Registered Nursing (CBRN)

Course Description: This activity brings together two nationally recognized experts to discuss the practical considerations of managing CLL with oral agents. It explores the benefits and challenges of oral CLL therapies, discusses strategies for monitoring and managing adverse events, and addresses barriers to adherence.